A New Line Of Sight
Into Targeted Cancer Therapies

View List

TRTC 2019 Consortium – Viewpoint is a Sponsor and CSO gives a Presentation

Sep 20, 2019

September 20, 2019 | Madison, WI.

Michael K. Schultz, PhD, Co-Founder and Chief Science Officer of Viewpoint, presented “212Pb & 203Pb Theranostics for Cancer” at the 2019 Targeted Radionuclide Therapy Consortium (TRTC) held at the University of Wisconsin-Madison. This three-day meeting focuses on advancing nuclear medicine science and education for the societal benefit of personalized healthcare, and personnel from fields of radiochemistry, radiology, radiation oncology, and medical physics are integrated at this event to fulfill this mission. Viewpoint Molecular Targeting is a proud Gold Industry Sponsor of the 2019 TRTC.

To see more: TRTC 2019